De-extinction startup Colossal Biosciences is in talks to raise new capital at a valuation between $20 billion and $30 billion, potentially doubling or tripling its previous valuation.
The funding round would represent significant growth for the biotech firm, which uses genetic engineering and synthetic biology to resurrect extinct species. Colossal has previously focused on reviving woolly mammoths and Tasmanian tigers through advanced biotechnology.
The reported valuation increase reflects growing investor interest in de-extinction and synthetic biology sectors. Colossal has secured previous funding from notable backers, including venture capital firms and tech entrepreneurs.
The company's technology aims to restore extinct species by editing the genomes of living relatives. If successful, the approach could have applications beyond de-extinction, including conservation efforts for endangered species and development of disease-resistant organisms.
Details on the timing of the funding round and lead investors have not been disclosed. The startup continues to advance its core projects while exploring the commercial and scientific potential of its platform.
Natural secured $30M in Series A funding led by Forerunner Ventures, bringing the company's total raised to $40M. The platform enables AI agents to execute autonomous payment transactions for enterprise operations.
Sarah Guo, Greylock's youngest general partner, founded Conviction in 2022 and has since backed six of the 21 AI-native companies valued at $10 billion or more.
Gritt has exited stealth mode with $34 million in funding to deploy robots for automating difficult tasks on construction sites, starting with solar plant installation.
Archer Aviation and defense contractor Anduril have jointly developed a new electric aircraft designed for both military and commercial deployment. The move signals how quickly air taxi companies are expanding beyond city commuting.